Roche Licenses Zymeworks Lung Cancer Therapy in Deal Worth Up to $813M

Zymeworks secured a licensing deal worth up to $813M with Roche for ZW209, an experimental lung cancer therapy designed to boost the body’s immune response against tumors. The agreement provides significant funding as the company advances its next-generation cancer treatment platform.